<DOC>
	<DOC>NCT02095990</DOC>
	<brief_summary>To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face, using a split-face randomization design, evaluating the MASI Score from baseline to week 4 and week 8, in both half-faces receiving active treatment vs. placebo. To assess the tolerance of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) on the face. To assess patients' satisfaction regarding Melanoderm 4% Crema after 8 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study</brief_title>
	<detailed_description />
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Adult women aged between 1865 years old. Fitzpatrick phototypes I to IV. Presenting moderate to severe facial melasma facial, with a basal Melasma Area and Severity Index (MASI Index) between 10 and 20. Women of childbearing potential must use an adequate contraceptive method to avoid pregnancy and must have a negative pregnancy test in a maximum of 72 hours before receiving the trial treatment. Breastfeeding women will not be included in the study. Having given freely and expressly her informed consent. Those with any history of allergy or hypersensitivity to a cosmetic product, hydroquinone, or one of the ingredients of the investigational products. Fitzpatrick phototype V. Skin pigmentation diseases different to melasma. Evidence of active cancer disease or diagnosis of cancer in the last year. Those receiving any topical or oral treatment that could interfere with melasma. Pregnant or breastfeeding women, or those expecting to get pregnant during the study. Evidence or suspicion of low compliance with the study visits and procedures. Participation in other clinical trial simultaneously or in the previous 3 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Facial Melasma</keyword>
</DOC>